Oral Isoxazoline Flea and Tick Preventive for Dogs (Fluralaner/Sarolaner/Afoxolaner, Seizure Risk in MDR1 Dogs, FDA Alert) — pet safety profile
Moderate riskIsoxazoline-class oral flea and tick preventives — fluralaner (Bravecto), sarolaner (Simparica), afoxolaner (NexGard), and lotilaner (Credelio) — represent the newest generation of parasiticides, delivered as flavored chewable tablets that provide systemic flea and tick kill for 30-90 days.
What is this product?
Isoxazoline-class oral flea and tick preventives — fluralaner (Bravecto), sarolaner (Simparica), afoxolaner (NexGard), and lotilaner (Credelio) — represent the newest generation of parasiticides, delivered as flavored chewable tablets that provide systemic flea and tick kill for 30-90 days. Isoxazolines selectively inhibit arthropod GABA-gated chloride channels and glutamate-gated chloride channels, causing parasite hyperexcitation and death. In 2018, the FDA issued a safety alert noting reports of neurological adverse events in dogs (muscle tremors, ataxia, seizures), particularly in breeds carrying the MDR1 (ABCB1) gene mutation (Collies, Australian Shepherds, Shelties) that impairs blood-brain barrier efflux of xenobiotics. These remain prescription-only medications requiring veterinary oversight. Despite the FDA alert, isoxazolines are considered safer overall than topical pyrethroids for multi-species households since they eliminate environmental contamination and cross-species contact risk.
What's in it
Click any compound name for its full safety profile, regulatory consensus, and exposure data.
Active Ingredient Class
Frequently asked questions
No FAQs generated.
Look up Oral Isoxazoline Flea and Tick Preventive for Dogs (Fluralaner/Sarolaner/Afoxolaner, Seizure Risk in MDR1 Dogs, FDA Alert) in the pets app
Search by ingredient, browse by category, or compare to alternatives in the live app.
Open in pets View raw API dataReference data, not professional advice. Aggregates publicly available regulatory and scientific information. Why we built ALETHEIA →